tert-butyl N-[(2S)-1-(4-methoxy-3-pyridin-4-ylanilino)-1-oxo-3-phenylpropan-2-yl]carbamate | 1401206-73-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl N-[(2S)-1-(4-methoxy-3-pyridin-4-ylanilino)-1-oxo-3-phenylpropan-2-yl]carbamate
• CAS: 1401206-73-2
• 化学式: C₂₆H₂₉N₃O₄
• 分子量: 447.534
• InChiKey: YGDNXNLKQCLHFV-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  89.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[(2S)-1-(4-methoxy-3-pyridin-4-ylanilino)-1-oxo-3-phenylpropan-2-yl]carbamate 在 三乙酰氧基硼氢化钠 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 (S)-N-(4-methoxy-3-(pyridin-4-yl)phenyl)-3-phenyl-2-(thiazol-4-ylmethylamino)propanamide
  参考文献：
  名称：

  Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus

  摘要：

  The discovery and initial optimization of a series of phenylalanine based agonists for GPR142 is described. The structure-activity-relationship around the major areas of the molecule was explored to give agonists 90 times more potent than the initial HTS hit in a human GPR142 inositol phosphate accumulation assay. Removal of CYP inhibition by exploration of the pyridine A-ring is also described. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.07.063
• 作为产物：
  描述：

  2-溴-4-硝基苯甲醚 在 四(三苯基膦)钯 、 10% Pd/C 、 氢气 、 碳酸氢钠 、 caesium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 50.0~70.0 ℃ 、101.33 kPa 条件下， 反应 38.0h， 生成 tert-butyl N-[(2S)-1-(4-methoxy-3-pyridin-4-ylanilino)-1-oxo-3-phenylpropan-2-yl]carbamate
  参考文献：
  名称：

  Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus

  摘要：

  The discovery and initial optimization of a series of phenylalanine based agonists for GPR142 is described. The structure-activity-relationship around the major areas of the molecule was explored to give agonists 90 times more potent than the initial HTS hit in a human GPR142 inositol phosphate accumulation assay. Removal of CYP inhibition by exploration of the pyridine A-ring is also described. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.07.063

文献信息

• Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus
  作者：Mike Lizarzaburu、Simon Turcotte、Xiaohui Du、Jason Duquette、Angela Fu、Jonathan Houze、Leping Li、Jinqian Liu、Michiko Murakoshi、Kozo Oda、Ryo Okuyama、Futoshi Nara、Jeff Reagan、Ming Yu、Julio C. Medina

  DOI：10.1016/j.bmcl.2012.07.063

  日期：2012.9

  The discovery and initial optimization of a series of phenylalanine based agonists for GPR142 is described. The structure-activity-relationship around the major areas of the molecule was explored to give agonists 90 times more potent than the initial HTS hit in a human GPR142 inositol phosphate accumulation assay. Removal of CYP inhibition by exploration of the pyridine A-ring is also described. (C) 2012 Published by Elsevier Ltd.